Prognosis - Posttransplantation Tumors

Determination of Tumor Origin Provides Treatment Strategies

Published in Cancer Weekly, July 31st, 1995

Use of PCR analysis to determine tumor origin in solid organ transplantation recipients has prognostic and therapeutic implications.

The majority of posttransplantation lymphoproliferative disorders (PTLDs) in bone marrow allograft recipients tend to be of donor origin as the host lymphoid system tends to be ablated by conditioning regimens. However, as few donor lymphoid cells are transferred with a solid organ allograft, it seems that the majority of PTLDs in these patients should be of host origin. The few histological studies done support this trend.

It has been noted, however, that many PTLDs appear preferentially to involve the allograft. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry